An event on fostering investment in the development of new antibacterial treatments was held on 23 October 2018 at the Palais des Nations, Geneva during the World Investment Forum (WIF).
Organised by UNCTAD and the World Health Organization (WHO), the event sought to identify the means for global collaboration to upsurge investment to address antimicrobial resistance (AMR).
It involved current global funding mechanisms and investors on AMR; representatives of biotechnology and biopharmaceutical industry; civil society and government entities with global outreach on AMR issues.
The meeting responds to the major global initiatives on AMR, such as the 2016 Davos Declaration, the WHO Global Action Plan on Antimicrobial Resistance, the G20 Leaders' commitment to action on AMR, including, inter alia, a new Global R&D Collaboration Hub, and the 2016 UN High-Level Political Declaration on Antimicrobial Resistance.
The event built on UNCTAD's ad hoc Expert Group Meeting on this issue organized in collaboration with WHO on 5 October 2017.
The event was attended by over one hundred participants from private sector, governments and civil society.